Biogen

Uses your system voice; voice and rate in settings.

Q864338Snapshot

≈ 5 min read

Names in other languages

  • PortuguêsBiogen Idec
  • العربيةبيوجن آيدك
  • DeutschBiogen
  • EnglishBiogen
  • فارسیبایوژن
  • FrançaisBiogen
  • NederlandsBiogen
  • 中文Biogen

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis.

The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues). The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis.

The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues). The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

Acquisition history

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list): Biogen Inc. Biogen IDEC Biogen (Est 1978) IDEC Pharmaceuticals Conforma Therapeutics (Acq 2006) Fumapharm AG (Acq 2006) Syntonix Pharmaceuticals (Acq 2007) Convergence Pharmaceuticals (Acq 2015) Nightstar Therapeutics (Acq 2019) Reata Pharmaceuticals (Acq 2023) Human Immunology Biosciences (HI-Bio) Apellis Pharmaceuticals (Announced 2026)

Pipeline

Investigational MS medicines: Daclizumab High-Yield Process (DAC HYP): is being developed as a potential once-monthly subcutaneous injection in the treatment of relapsing-remitting multiple sclerosis (RRMS). DAC HYP is being developed in collaboration with Abbvie, Inc. In June 2014, the companies announced positive top-line results from the Phase III DECIDE clinical trial, where DAC HYP demonstrated superiority over interferon beta-1a in annualized relapse rate.

Anti-LINGO-1 (BIIB033) (Opicinumab): is the first candidate being investigated for its potential to remyelinate and repair neurons damaged by MS. Phase II trials were conducted in 2016 but failed to reach their goals. Biogen has several candidates in Phase 1 and 2 clinical trials in neurodegenerative and immunological diseases: Phase 2a: anti-LINGO-1 molecule (Opicinumab) in acute optic neuritis Phase 2b: anti-TWEAK monoclonal antibody in lupus nephritis Phase 2a: STX-100 in patients with idiopathic pulmonary fibrosis Phase 2: Neublastin for neuropathic pain in 2013 Phase 2: BIIB080 for neurodegenerative diseases in 2026, targeting tau protein Phase 1/2: BIIB067 (ISIS-SOD1 Rx ) for amyotrophic lateral sclerosis, in collaboration with Ionis Biogen also has several development agreements in place with Ionis Pharmaceuticals to collaborate to leverage antisense technology in advancing the treatment of neurological disorders.

In February 2012, Biogen formed a joint venture with Samsung, Samsung Bioepis. Samsung acquired Biogen's interest in the venture in January 2022 for up to $2.3 billion.

In early 2014, Biogen entered into an agreement with Eisai to jointly develop and commercialize two of their candidates for Alzheimer's disease, which have the potential to reduce Aβ plaques that form in the brains of patients, as well as to slow the formation of new plaques, potentially improving symptoms and suppressing disease progression. Biogen also has since 2015 an agreement with AGTC to develop gene therapy for several genetic diseases, including X-linked retinoschisis (XLRS) and X-linked Retinitis pigmentosa (XLRP) ophthalmologic diseases.

Biogen paid AGTC $124 million, including an equity investment of $30 million, and offered up to $1.1 billion in future milestone payments. In March 2019, Biogen halted Phase 3 trials of Alzheimer's disease drug Aducanumab after "an independent group's analysis show[ed] that the trials were unlikely to 'meet their primary endpoint.'"

However, in October 2019 they reversed their plans and said that they would be pursuing US FDA approval for Aducanumab. The reversal came after Biogen said a new analysis of a larger patient pool showed promising results. In July 2020, Biogen completed submission of a Biologics license application (BLA) to the FDA for review, and requested accelerated review.

However, an advisory panel for the FDA voted against approval of this drug. On June 7, 2021, the FDA granted approval of Aducanumab for the treatment of Alzheimer's disease. Aducanumab was approved using the accelerated approval pathway, and Biogen will be required to conduct a post-approval clinical trial to verify clinical benefit for continued approval.

Lawsuits

In September 2022, Biogen agreed to pay $900 million to the U.S. federal government, states, and a whistleblower. Biogen had bribed doctors between 2009 and 2014 to increase prescriptions of Avonex, Tysabri, and Tecfidera (all for multiple sclerosis).

See also

Neurological diseases Kenneth Murray Eisai Tim Harris (biochemist)

Text derived from https://en.wikipedia.org/w/index.php?oldid=1374371502 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

35 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.